CDEK by Data4ThePeople
Sign in Sign up
← All organizations

Melinta Therapeutics

For profitContributed to NMEWebsite ↗

Also known as: CMO, MelintaTherapeutics, Inc. | CMO, MelintaTtherapeutics, Inc. | MELINTA | MELINTA THERAP | Melinta Therapeutics | Melinta Therapeutics, Inc. | Melinta Therapeutics, LLC | Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) | Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 3

First clinical trial

Oct 1, 2007

First marketed drug

Aug 6, 2014

First NDA

Aug 6, 2014

Last known activity

Oct 15, 2025

Timeline

2000s

  1. Jul 1, 2000

    Melinta Therapeutics— Founded

2010s

  1. Jun 19, 2017

    delafloxacin meglumine— NDA Organization

  2. Jun 19, 2017

    delafloxacin meglumine— NDA Secondary Org

  3. Aug 9, 2017

    Cempra Inc— Acquired

2020s

  1. Mar 16, 2020

    Tetraphase Pharmaceuticals— Acquired

Drugs by trial phase (26 distinct, 48 trials)

Phase 1 (1 own, 2 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (2)

Subsidiaries (2 direct, 2 total across the full acquisition tree)

Recent trials (31)

Details

Founded
New Haven, CT, US Jul 1, 2000
First NDA
Aug 6, 2014
Last known activity
Oct 15, 2025

Designations held

  • Fast track
  • Priority review

Notes

Originally known as Rib-X Pharmaceuticals